Dr. Daniel J. Canter, MD

Dr. Canter practices at Georgia Urology PA in Cumming, Georgia.

Dr. Canter's NPI, 1689730061, was assigned on December 29, 2006. Dr. Canter graduated from George Washington University School of Medicine and Health Sciences in 2004. Dr. Canter holds Georgia license 65462.

Dr. Canter's primary practice is Georgia Urology PA, at 1800 Northside Forsyth Dr, Cumming, GA 30041 in Forsyth County. The practice phone is (770) 889-9737.

Dr. Canter's primary practice is Georgia Urology PA in Cumming, Georgia. Dr. Canter is also affiliated with Northside Hospital Forsyth. The medical group on file is Georgia Urology. Dmand AI also links Dr. Canter to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Canter practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Canter's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Canter is board certified in urology by the American Board of Urology. Dmand AI has Dr. Canter's licenses on file in 4 states: Georgia, Louisiana, Florida and Pennsylvania.

Dmand AI lists enlarged prostate, erectile dysfunction, kidney stone disease, prostate cancer, urinary endoscopy and UTI among the conditions Dr. Canter treats.

CMS data shows 147 Medicare services from Dr. Canter across 4 procedure codes in 2024, for 79 Medicare patients. Medicare paid $10,859 for them. Every service was in an office.

CMS counts 79 Medicare patients who saw Dr. Canter in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Canter's median patient age at 74, with 15% women.

In 2024, Dr. Canter wrote 123 Medicare Part D claims for 26 patients. 39% of them were for generic drugs. CMS names the drug for 98 of them, across 4 drugs with 11 or more claims each, at $707,122 in total drug cost. In 2023, CMS named 336 claims across 8 drugs.

Dr. Canter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Canter as offering telehealth.

Dmand AI links 117 papers to Dr. Canter, published from 2008 to 2025. 2019 was the busiest year, with 9. The most frequent topics are Kidney Neoplasms, Nephrectomy and Urinary Bladder Neoplasms. Dr. Canter has published most often in Can J Urol. Dr. Canter's most frequent co-authors are David Yen Tang Chen, MD, Richard Evan Greenberg, MD and Stephen Anthony Boorjian, MD.

Dmand AI links Dr. Canter to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Urinary Bladder Neoplasms and Prostatic Diseases.

CMS Open Payments shows 525 general payments to Dr. Canter from 46 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Janssen Pharmaceuticals, Inc paid the most, $118,567.

Dr. Canter graduated from George Washington University School of Medicine and Health Sciences in 2004.

Dr. Canter is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.